Today: 16 April 2026
Subscribe
Browse Category

NASDAQ:DNN 26 March 2026

Meta Layoffs Test $3 Trillion Hopes as AI Spending Surges

Meta Layoffs Test $3 Trillion Hopes as AI Spending Surges

Denison Mines shares fell 5.5% to $3.38 Thursday as nearly 19 million shares traded, outpacing declines in other uranium stocks. Investors reacted to the company’s C$600 million capital estimate for its Phoenix uranium project, which is set to begin site work this month after final federal approval. Denison raised US$345 million in convertible notes last year but flagged refinancing and debt risks in recent filings.
26 March 2026
··

Stock Market Today

  • NOV Stock Valuation: Contrasting Short-Term Price Moves and Long-Term Momentum
    April 16, 2026, 1:11 AM EDT. NOV (ticker: NOV) has gained 4.6% over one month and 5.5% in three months, yet its 12-month total return stands at a robust 64%. Shares currently trade at $19.02, slightly below a fair value estimate of $20.10, suggesting a modest valuation gap rooted in expectations of future cash flow and execution. Contrastingly, a discounted cash flow (DCF) model values NOV at $29.08, implying a 34.6% undervaluation. The stock's outlook depends on sustained global energy infrastructure investments, especially in LNG and gas processing. However, risks from tariffs, inflation, and pricing pressure could impact margins. Investors are advised to assess these conflicting signals and consider broader opportunities in energy infrastructure sectors as momentum builds steadily over the long term.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 16.04.2026

16 April 2026
LIVEMarkets rolling coverageStarted: April 16, 2026, 12:00 AM EDTUpdated: April 16, 2026, 1:14 AM EDT NOV Stock Valuation: Contrasting Short-Term Price Moves and Long-Term Momentum April 16, 2026, 1:11 AM EDT. NOV (ticker: NOV) has gained 4.6% over one month and 5.5% in three months, yet its 12-month total return stands at a robust 64%. Shares currently trade at $19.02, slightly below a fair value estimate of $20.10, suggesting a modest valuation gap rooted in expectations of future cash flow and execution. Contrastingly, a discounted cash flow (DCF) model values NOV at $29.08, implying a 34.6% undervaluation. The stock's outlook
Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

16 April 2026
Norse Atlantic Airways has canceled all planned summer flights from Los Angeles to London Gatwick, Paris, and Rome, citing surging jet fuel costs. The airline launched a $110 million rights issue, secured a $70 million bridge loan, and withdrew its 2026 outlook. Routes disappeared from booking systems on April 14. Norse had been the only scheduled operator on the Gatwick-Los Angeles route.
S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

16 April 2026
The S&P 500 closed at a record 7,022.95 and the Nasdaq at 24,016.02 on Wednesday, erasing losses from the March selloff tied to the Feb. 28 conflict. Bank of America reported $8.6 billion in first-quarter net income, up 17%, while Morgan Stanley posted record revenue. Talks between Washington and Tehran raised hopes for easing oil supply fears, but Brent crude stayed elevated at $94.93 a barrel.
Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

16 April 2026
China is considering export restrictions on advanced solar-manufacturing equipment to the U.S., potentially affecting Tesla’s plans for new factories, sources told Reuters. Tesla aims to buy $2.9 billion in solar-panel equipment from China and expand U.S. solar production. China produces over 80% of global solar panel components. No final decision has been made, and consultations remain preliminary.
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

15 April 2026
Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
Go toTop